Gemcitabina Aurobindo Pharma Italia 40 mg/ml concentrato per soluzione per infusione

DRUG2 trials

Sponsors

Humanitas Mirasole S.p.A., Universita' Degli Studi Di Torino

Conditions

Non Small Cell Lung CancerRecurrent Metastatic Nasopharingeal Carcinoma

Phase 2

DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

Not yet recruitingCTIS2026-525268-16-00

Universita' Degli Studi Di TorinoNon Small Cell Lung Cancer

Target: 962Updated: 2026-10-19

Phase 3

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Not yet recruitingCTIS2025-522472-85-00

Humanitas Mirasole S.p.A.Recurrent Metastatic Nasopharingeal Carcinoma

Target: 49Updated: 2026-01-08